J Korean Med Sci.  2007 Apr;22(2):209-212. 10.3346/jkms.2007.22.2.209.

Short-term Efficacy of Monthly Pamidronate Infusion in Patients with Osteogenesis Imperfecta

• Choi JH
• Shin YL
• Yoo HW

• KMID: 1713163
• DOI: http://doi.org/10.3346/jkms.2007.22.2.209

Abstract

We evaluated the efficacy of a monthly infusion of pamidronate on the frequency of fractures, biochemical effects, and bone mineral density in children with osteogenesis imperfecta. Eleven patients from 0.9 to 13.8 yr of age were included in this study. The patients were administered pamidronate intravenously (30 mg/m2) over a 4-hr period monthly for a period ranging from 6 to 37 months. Height and weight Z-scores did not change significantly. The frequency of fractures was decreased from 2.3+/-1.01 times per year before treatment to 0.6+/-0.69 times per year during treatment. There were no long-term changes in biochemical markers during pamidronate therapy. The mean bone mineral density of the spine and femur increased significantly. Monthly intravenous pamidronate therapy decreased frequencies of fracture and increased bone mineral density without significant adverse events in Korean patients with osteogenesis imperfecta.

Keyword

Osteogenesis Imperfecta; Pamidronate

MeSH Terms

Treatment Outcome
Osteogenesis Imperfecta/complications/diagnosis/*drug therapy
Male
Korea
Infusions, Intravenous
Infant
Humans
Fractures, Spontaneous/etiology/*prevention & control
Female
Diphosphonates/*administration & dosage
Child, Preschool
Child
Bone Density/*drug effects
Anti-Inflammatory Agents/administration & dosage
Adolescent

Reference

1. Sykes B, Ogilvie D, Wordsworth P, Wallis G, Mathew C, Beighton P, Nicholls A, Pope FM, Thompson E, Tsipouras P. Consistent linkage of dominantly inherited osteogenesis imperfecta to the type I collagen loci: COL1A1 and COL1A2. Am J Hum Genet. 1990. 46:293–307.

2. Marini JC, Chernoff EJ. Cassidy SB, Allanson JE, editors. Osteogenesis imperfecta. Management of genetic syndromes. 2001. Philadelphia: Wiley-Liss Inc;281–300.

3. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979. 16:101–116.

4. Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet. 2004. 363:1377–1385.

5. Lee YS, Low SL, Lim LA, Loke KY. Cyclic pamidronate infusion improves bone mineralisation and reduces fracture incidence in osteogenesis imperfecta. Eur J Pediatr. 2001. 160:641–644.

6. Astrom E, Soderhall S. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child. 2002. 86:356–364.

7. Bembi B, Parma A, Bottega M, Ceschel S, Zanatta M, Martini C, Ciana G. Intravenous pamidronate treatment in osteogenesis imperfecta. J Pediatr. 1997. 131:622–625.

8. Falk MJ, Heeger S, Lynch KA, DeCaro KR, Bohach D, Gibson KS, Warman ML. Intravenous bisphosphonate therapy in children with osteogenesis imperfecta. Pediatrics. 2003. 111:573–578.

9. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998. 339:947–952.

10. Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, Glorieux FH. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab. 2000. 85:1846–1850.

11. Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH. Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab. 2003. 88:986–992.

12. Rauch F, Travers R, Plotkin H, Glorieux FH. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest. 2002. 110:1293–1299.

13. Zeitlin L, Rauch F, Plotkin H, Glorieux FH. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics. 2003. 111:1030–1036.

14. Zacharin M, Bateman J. Pamidronate treatment of osteogenesis imperfecta--lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response. J Pediatr Endocrinol Metab. 2002. 15:163–174.

15. References for Korean children's physical development. Korean Pediatric Society. 1998. accessed 16 May 2006. Available at http://www.pediatrics.or.kr/default.asp .

16. Bleck EE. Nonoperative treatment of osteogenesis imperfecta: orthotic and mobility management. Clin Orthop Relat Res. 1981. 159:111–122.

17. Kim BY, Kim YG, Kim YJ, Yoo KH, Lee JW, Kim SK. A study of bone marrow density in Korean children of normal growth and development. J Korean Pediatr Soc. 1995. 38:612–618.

18. Lee SW, Kim HJ, Cho JH, Lee HS, Jung YM, Kim DJ, Lee KW, Chung YS. Effects of pamidronate treatment on osteogenesis imperfecta. J Korean Soc Endocrinol. 2004. 19:485–491.

19. Cho TJ, Park MS, Choi IH, Chung CY, Yoo WJ. Efficacy of cyclic intravenous pamidronate therapy for children with osteogenesis imperfecta. J Korean Orthop Assoc. 2003. 38:741–747.

20. Srivastava T, Alon US. The role of bisphosphonates in diseases of childhood. Eur J Pediatr. 2003. 162:735–751.

21. Lindsay R. Modeling the benefits of pamidronate in children with osteogenesis imperfecta. J Clin Invest. 2002. 110:1239–1241.

22. Srivastava T, Alon US. Bisphosphonates: from grandparents to grandchildren. Clin Pediatr (Phila). 1999. 38:687–702.

23. Vasikaran SD. Bisphosphonates: an overview with special reference to alendronate. Ann Clin Biochem. 2001. 38:608–623.

24. Vitte C, Fleisch H, Guenther HL. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology. 1996. 137:2324–2333.

25. Brumsen C, Hamdy NA, Papapoulos SE. Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine (Baltimore). 1997. 76:266–283.